The monitoring of antiaggregation effect of acetylsalicylic
acid therapy by measuring serum thromboxane B-2 in patients
with coronary artery bypass grafting

J 2016

The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting

KLASIC, A.; N. LAKUSIC; L. GASPAR a Peter KRUŽLIAK

Základní údaje

Originální název

The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting

Autoři

KLASIC, A.; N. LAKUSIC; L. GASPAR a Peter KRUŽLIAK

Vydání

BLOOD COAGULATION & FIBRINOLYSIS, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2016, 0957-5235

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.367

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00113805

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

acetylsalicylic acid resistance; cardiovascular disease; impedance aggregometry; thromboxane B-2

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 4. 2020 14:24, Mgr. Tereza Miškechová

Anotace

V originále

Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B-2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B-2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P<0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.

Citovat

KLASIC, A.; N. LAKUSIC; L. GASPAR a Peter KRUŽLIAK. The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting. BLOOD COAGULATION & FIBRINOLYSIS. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2016, roč. 27, č. 4, s. 370-373. ISSN 0957-5235. Dostupné z: https://doi.org/10.1097/MBC.0000000000000438.

@article{1649976,
   author = {Klasic, A. and Lakusic, N. and Gaspar, L. and Kružliak, Peter},
   article_location = {PHILADELPHIA},
   article_number = {4},
   doi = {https://doi.org/10.1097/MBC.0000000000000438},
   keywords = {acetylsalicylic acid resistance; cardiovascular disease; impedance aggregometry; thromboxane B-2},
   language = {eng},
   issn = {0957-5235},
   journal = {BLOOD COAGULATION & FIBRINOLYSIS},
   title = {The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting},
   url = {https://insights.ovid.com/article/00001721-201606000-00003},
   volume = {27},
   year = {2016}
}

TY  - JOUR
ID  - 1649976
AU  - Klasic, A. - Lakusic, N. - Gaspar, L. - Kružliak, Peter
PY  - 2016
TI  - The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting
JF  - BLOOD COAGULATION & FIBRINOLYSIS
VL  - 27
IS  - 4
SP  - 370-373
EP  - 370-373
PB  - LIPPINCOTT WILLIAMS & WILKINS
SN  - 09575235
KW  - acetylsalicylic acid resistance
KW  - cardiovascular disease
KW  - impedance aggregometry
KW  - thromboxane B-2
UR  - https://insights.ovid.com/article/00001721-201606000-00003
L2  - https://insights.ovid.com/article/00001721-201606000-00003
N2  - Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B-2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B-2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P<0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
ER  -

KLASIC, A.; N. LAKUSIC; L. GASPAR a Peter KRUŽLIAK. The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B-2 in patients with coronary artery bypass grafting. \textit{BLOOD COAGULATION \&{}amp; FIBRINOLYSIS}. PHILADELPHIA: LIPPINCOTT WILLIAMS \&{}amp; WILKINS, 2016, roč.~27, č.~4, s.~370-373. ISSN~0957-5235. Dostupné z: https://doi.org/10.1097/MBC.0000000000000438.

Přehled o publikaci